Enzalutamide (Xtandi®)

Common name: Enzalutamide
Brand name: Xtandi®
 

What is Enzalutamide?

Enzalutamide is an anti-androgen therapy that blocks the action of male hormones and is used to treat metastatic castration-resistant prostate cancer.

Enzalutamide has been approved for the following uses:
  • It is given to men who previously received docetaxel chemotherapy
  • It is also given to men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy (ADT)

How is Enzalutamide administered?

Enzalutamide is administered orally as a soft gelatin capsule.
 

What are possible side effects of this treatment?

Everyone responds differently to hormone therapy – some experience many side effects while others experience very few. The table below lists some side effects experienced by those who received enzalutamide. Tell your health care team about side-effects you are experiencing so they know how best to help you manage them.
  • Back pain
  • Diarrhea
  • Joint pain
  • Headaches
  • Hot flashes
  • Muscle pain
  • Weakness


Is Enzalutamide covered in my province or territory?

Enzalutamide is covered by all provincial/territorial drug programs.

Xtandi Patient Assistance Program

Patient Assistance Programs are offered by pharmaceutical companies to provide medications to those who cannot afford to pay for their medicine.

Please call 1-855-898-2634 for more information and to see if you qualify for this program.

Enzalutamide has been approved for use by Health Canada and has been recommended for funding by the pan-Canadian Oncology Drug Review (pCODR) for both indications.

Read pCODR’s decisions for enzalutamide (xtandi®) below:

Enzalutamide - July 2013

Enzalutamide - June 2015

For more information on pCODR, please visit www.pcodr.ca

 
Last Updated: June 2018

Prostate Cancer Awareness Month

Donate Now!


Subscribe to our free monthly e-newsletter!

* indicates required

 





 
PCC Spotlight
Prostate Cancer Canada launches first national program in radionuclide therapy

Toronto, June 27, 2018 – Canadian researchers are leading the future of treatment for men with advanced prostate cancer in this country, with a new Prostate Cancer Canada grant funded by the Movember Foundation.
More

Honouring dad this Father’s Day the Canadian way: In plaid

TORONTO, ON – (May 8, 2018) – Plaid replaces business-casual on Friday, June 15 as hundreds of thousands of Canadians don the iconic Canadian attire all to honour dad and end prostate cancer.
More

The Finger – A tried and true method to save lives

TORONTO, CANADA (May 8, 2018) – Every day, more and more methods to detect prostate cancer are being explored, but the tried and true methods of a digital rectal examination (DRE) – where a healthcare professional inserts a gloved finger into the rectum to check for abnormalities, paired with a blood test known as the prostate-specific antigen (PSA) test – which you can get through your family doctor, are still the long-standing proven ways to save a life.
More


Click here for news archive